|
1
|
Jemal A, Murray T, Ward E, Samuels A,
Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics. CA
Cancer J Clin. 55:10–30. 2005.
|
|
2
|
Rabenstein DL: Heparin and heparan
sulfate: structure and function. Nat Prod Rep. 19:312–331. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hirsh J, Warkentin TE, Shaughnessy SG,
Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM and Dalen JE:
Heparin and low-molecular-weight heparin: mechanisms of action,
pharmacokinetics, dosing, monitoring, efficacy and safety. Chest.
119:S64–S94. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Akl EA, Rohilla S, Barba M, Sperati F,
Terrenato I, Muti P, Bdair F and Schünemann HJ: Anticoagulation for
the initial treatment of venous thromboembolism in patients with
cancer: a systematic review. Cancer. 113:1685–1694. 2008.
View Article : Google Scholar
|
|
5
|
Robert F, Busby E, Marques MB, Reynolds RE
and Carey DE: Phase II study of docetaxel plus enoxaparin in
chemotherapy-naive patients with metastatic non-small cell lung
cancer: preliminary results. Lung Cancer. 42:237–245. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Altinbas M, Coskun HS, Er M, Ozkan O, Eser
B, Unal A, Cetin M and Soyuer S: A randomized clinical trial of
combination chemotherapy with and without low-molecular-weight
heparin in small cell lung cancer. J Thromb Haemost. 2:1266–1271.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Akl EA, van Doormaal FF, Barba M, Kamath
G, Kim SY, Kuipers S, Middeldorp S, Yosuico V, Dickinson HO and
Schünemann HJ: Parenteral anticoagulation may prolong the survival
of patients with limited small cell lung cancer: a Cochrane
systematic review. J Exp Clin Cancer Res. 27:42008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Von Tempelhoff GF, Harenberg J, Niemann F,
Hommel G, Kirkpatrick CJ and Heilmann L: Effect of low molecular
weight heparin (Certoparin) versus unfractionated heparin on cancer
survival following breast and pelvic cancer surgery: A prospective
randomized double-blind trial. Int J Oncol. 16:815–824. 2000.
|
|
9
|
Nagy Z, Turcsik V and Blaskó G: The effect
of LMWH (Nadroparin) on tumor progression. Pathol Oncol Res.
15:689–692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Constantini S, Kanner A, Friedman A,
Shoshan Y, Israel Z, Ashkenazi E, Gertel M, Even A, Shevach Y,
Shalit M, Umansky F and Rappaport ZH: Safety of perioperative
minidose heparin in patients undergoing brain tumor surgery: a
prospective, randomized double-blind study. J Neurosurg.
94:918–921. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kakkar AK, Levine MN, Kadziola Z, Lemoine
NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M and Williamson
RC: Low molecular weight heparin, therapy with dalteparin, and
survival in advanced cancer: the Fragmin Advanced Malignancy
Outcome Study (FAMOUS). J Clin Oncol. 22:1944–1948. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Klerk CP, Smorenburg SM, Otten HM, Lensing
AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van
Tienhoven G and Büller HR: The effect of low molecular weight
heparin on survival in patients with advanced malignancy. J Clin
Oncol. 23:2130–2135. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuderer NM, Ortel TL and Francis CW:
Impact of venous thromboembolism and anticoagulation on cancer and
cancer survival. J Clin Oncol. 27:4902–4911. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kragh M, Binderup L, Vig Hjarnaa PJ, Bramm
E, Johansen KB and Frimundt Petersen C: Non-anti-coagulant heparin
inhibits metastasis but not primary tumor growth. Oncol Rep.
14:99–104. 2005.PubMed/NCBI
|
|
15
|
Ludwig RJ, Boehme B, Podda M, Henschler R,
Jager E, Tandi C, Boehncke WH, Zollner TM, Kaufmann R and Gille J:
Endothelial p-selectin as a target of heparin action in
experimental melanoma lung metastasis. Cancer Res. 64:2743–2750.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mellor P, Harvey JR, Murphy KJ, Pye D,
O’Boyle G, Lennard TWJ, Kirby JA and Ali S: Modulatory effects of
heparin and short-length oligosaccharides of heparin on the
metastasis and growth of LMD MDA-MB 231 breast cancer cells in
vivo. Br J Cancer. 97:761–768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smorenburg SM, Vink R, Otten HM, Swaneveld
F and Büller HR: The effects of vitamin K antagonists on survival
of patients with malignancy: a systematic analysis. Thromb Haemost.
86:1586–1587. 2001.PubMed/NCBI
|
|
18
|
Niers TM, Klerk CP, DiNisio M, van Noorden
CJ, Büller HR, Reitsma PH and Richel DJ: Mechanisms of
heparin-induced anti-cancer activity in experimental cancer models.
Crit Rev Oncol Hematol. 61:195–207. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takahashi H, Ebihara S, Okazaki T and
Yamaya M: A comparison of the effects of unfractionated heparin,
dalteparin and danaparoid on vascular endothelial growth
factor-induced tumor angiogenesis and heparanase activity. Br J
Pharmacol. 146:333–343. 2005. View Article : Google Scholar
|
|
20
|
Mousa SA and Petersen LJ: Anti-cancer
properties of low-molecular-weight heparin: preclinical evidence.
Thromb Haemost. 102:258–267. 2009.PubMed/NCBI
|
|
21
|
Hostettler N, Naggi A, Torri G,
Ishai-Michaeli R, Casu B, Vlodavsky I and Borsig L: P-selectin- and
heparanase-dependent antimetastatic activity of non-anticoagulant
heparins. FASEB J. 21:3562–3572. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stevenson JL, Choi SH and Varki A:
Differential metastasis inhibition by clinically relevant levels of
heparins – correlation with selectin inhibition, not antithrombotic
activity. Clin Cancer Res. 11:7003–7011. 2005.PubMed/NCBI
|
|
23
|
Vlodavsky I, Goldshmidt O, Zcharia E,
Atzmon R, Rangini-Guatta Z, Elkin M, Peretz T and Friedmann Y:
Mammalian heparanase: involvement in cancer metastasis,
angiogenesis and normal development. Semin Cancer Biol. 12:121–129.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sasaki M, Ito T, Kashima M and Miura M:
Erythromycin and clarithromycin modulation of growth factor-induced
expression of heparanase mRNA on human lung cancer cells in vitro.
Mediators Inflamm. 10:259–267. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Edovitsky E, Elkin M, Zcharia E, Peretz T
and Vlodavsky I: Heparanase gene silencing, tumor invasiveness,
angiogenesis, and metastasis. J Natl Cancer Inst. 96:1219–1230.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Joyce JA, Freeman C, Meyer-Morse N, Parish
CR and Hanahan D: A functional heparan sulfate mimetic implicates
both heparanase and heparan sulfate in tumor angiogenesis and
invasion in a mouse model of multistage cancer. Oncogene.
24:4037–4051. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Uno F, Fujiwara T, Takata Y, Ohtani S,
Katsuda K, Takaoka M, Ohkawa T, Naomoto Y, Nakajima M and Tanaka N:
Antisense-mediated suppression of human heparanase gene expression
inhibits pleural dissemination of human cancer cells. Cancer Res.
61:7855–7860. 2001.PubMed/NCBI
|
|
28
|
Steeg PS, Bevilacqua G, Kopper L,
Thorgeirsson UP, Talmadge JE, Liotta LA and Sobel ME: Evidence for
a novel gene associated with low tumor metastatic potential. J Natl
Cancer Inst. 80:200–204. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kawakubo Y, Sato Y, Koh T, Kono H and
Kameya T: Expression of nm23 protein in pulmonary adenocarcinomas:
inverse correlation to tumor progression. Lung Cancer. 17:103–113.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Steeg PS, Ouatas T, Halverson D, Palmieri
D and Salerno M: Metastasis suppressor genes: basic biology and
potential clinical use. Clin Breast Cancer. 4:51–62. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma W, Chen J, Xue X, Wang Z, Liu H, Wang
T, Bai Y, Tang SC and Zhou Q: Alteration in gene expression profile
and biological behavior in human lung cancer cell line NL9980 by
nm23-H1 gene silencing. Biochem Biophys Res Commun. 371:425–430.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Humphries MJ: Integrin structure. Biochem
Soc Trans. 28:311–339. 2000. View Article : Google Scholar
|
|
33
|
Giancotti FG and Ruoslahti E: Integrin
signaling. Science. 285:1028–1032. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miranti CK and Brugge JS: Sensing the
environment: a historical perspective on integrin signal
transduction. Nat Cell Biol. 4:E83–E90. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Westermarck J and Kähäri VM: Regulation of
matrix metalloproteinase expression in tumor invasion. FASEB J.
13:781–792. 1999.PubMed/NCBI
|
|
36
|
Zeng ZS, Cohen AM and Guillem JG: Loss of
basement membrane type IV collagen is associated with increased
expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during
human colorectal tumorigenesis. Carcinogenesis. 20:749–755. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fareed J, Leong WL, Hoppensteadt DA, Jeske
WP, Walenga J, Wahi R and Bick RL: Generic low-molecular-weight
heparins: some practical considerations. Semin Thromb Hemost.
30:703–713. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Deepa PR and Varalakshmi P: The
cytoprotective role of a low-molecular-weight heparin fragment
studied in an experimental model of glomerulotoxicity. Eur J
Pharmacol. 478:199–205. 2003. View Article : Google Scholar : PubMed/NCBI
|
